SecBot SecBot
SECBOTREPLAY Home › Report › OTLK

OTLK · Outlook Therapeutics filed an 8-K disclosing a registered direct…

Outlook Therapeutics, Inc. · 8-K filed May 29, 2026 at 16:30 ET

At the news

BEARISHIMPACT 6/10

8-K filed May 29, 2026 at 16:30 ET

Outlook Therapeutics filed an 8-K disclosing a registered direct offering of 8,539,709 shares of common stock to GMS Ventures and Investments, priced under an existing effective shelf registration statement. The offering represents approximately 9.6% dilution relative to the $89M market cap, providing near-term cash but pressuring the stock via share count expansion.

  • Registered direct offering of 8,539,709 shares to GMS Ventures and Investments
  • Securities purchase agreement dated May 28, 2026
  • Offering made under effective S-3 shelf (File No. 333-278340)
  • Shares represent ~9.6% of pre-offering shares outstanding based on $89M market cap

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access